Skip to content

Impact of a Virtual Reality-based Mindfulness Program on Clinician Wellness

Impact of a Virtual Reality-based Mindfulness Program on Clinician Wellness

Status
Not yet recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06246539
Enrollment
32
Registered
2024-02-07
Start date
2026-09-01
Completion date
2028-07-31
Last updated
2026-08-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Wellness, Psychological

Brief summary

Burnout shares symptoms with anxiety and depression. While there is no single intervention for burnout, there are validated interventions (which are amenable to virtual reality (VR)) for anxiety and depression. UMassMemorial data from the Professional Well-Being Academic Consortium show that MD burnout and distress has increased since 2020. The investigators believe providing clinicians with a unique tool (VR) will be a feasible and efficacious way to tackle distress. It is known that only 1% of our MDs have done mindfulness training but nearly 50% are interested in doing so. Therefore, a self-administrable, interactive mindfulness program delivered over VR has great potential to reach clinicians who want to practice a more active form of mindfulness at a time convenient to them. The results of the study will provide preliminary evidence to determine if a take-home VR mindfulness program decreases clinician stress.

Detailed description

Cohorts 1 will be the intervention group Cohorts 2 will be the controls. Study endpoints include results from the following questionnaires: 1. PROMIS - Short Form Anxiety (8 questions) 2. PROMIS - Short Form Depression (8 questions) 3. Perceived Stress Scale (10 questions) 4. Connor-Davidson Brief Resilience Scale (10 questions) 5. System Usability Scale (10 questions) The intervention is a 12-week mindfulness-based VR intervention. Cohort 1 will complete the questionnaires 1-4 at baseline (just before the intervention). They will be sent twice weekly reminders to use the VR for the duration of the 12-week intervention. After 12 weeks Cohort 1 will retake questionnaires 1-4 and take questionnaire 5, while Cohort 2 will then take questionnaires 1-4 and be provided the VR headsets. After another 12 weeks, Cohort 1 will take questionnaires 1-4 and be done with the study, while Cohort 2 will take questionnaires 1-5. After 12 more weeks, Cohort 2 will take questionnaires 1-4 and be done with the study.

Interventions

BEHAVIORALVR mindfulness

VR-based mindfulness

Sponsors

University of Massachusetts, Worcester
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
NONE

Eligibility

Sex/Gender
ALL
Healthy volunteers
Yes

Inclusion criteria

* physician or APP employed by the Medical Group

Exclusion criteria

* Not willing to receive 2 texts per week

Design outcomes

Primary

MeasureTime frameDescription
PROMIS - anxietyat baseline, after 12 weeks, then after another 12 weeks. We will compare results of the intervention group at 12 and 24 weeks to their baseline.PROMIS Short Form - anxiety scale. Scores of 8-40; Higher is a worse outcome.
PROMIS - Depressionat baseline, after 12 weeks, then after another 12 weeks. We will compare results of the intervention group at 12 and 24 weeks to their baseline.PROMIS Short Form - Depression scale. Scores of 8-40; Higher is a worse outcome.
Resiliencyat baseline, after 12 weeks, then after another 12 weeks. We will compare results of the intervention group at 12 and 24 weeks to their baseline.Connor-Davidson Resiliency Scale. Scores of 0-40; Higher score is better.
Stress scaleat baseline, after 12 weeks, then after another 12 weeks. We will compare results of the intervention group at 12 and 24 weeks to their baseline.Perceived Stress Score. Scores of 0-40; Higher score is worse.
Usabilityafter 12 weeks we will dertermine the usability of the VR intervention in the intervention groupUsability scale. Scores of 10-50; Higher score is better.

Countries

United States

Contacts

CONTACTSteven Bird, MD
steven.bird@umassmemorial.org508-421-1422
PRINCIPAL_INVESTIGATORSteven Bird, MD

University of Massachusetts, Worcester

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Aug 18, 2026